Indication
For the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older.
Medicine details
- Medicine name:
- vamorolone (Agamree)
- SMC ID:
- SMC2721
- Pharmaceutical company
- Santhera Pharmaceuticals
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Publication due date:
- 13 January 2025
- SMC meeting date:
- 03 December 2024
- Patient group submission deadline:
- 01 October 2024